Takeda forecasts 17% profit decline on Velcade US exclusivity loss
Updated : May 14, 2018 12:24 PM IST
The decline, which is likely to be partly offset by growing sales of drugs such as bowel disease treatment Entyvio and heartburn and ulcer drug Takecab, underscores Takeda's need to bolster its pipeline.
It also comes days after it agreed to a record-breaking $62 billion deal to acquire London-listed Shire.
Entyvio sales grew 41% to 201.4 billion yen, with Takecab sales up 62% to 55.1 billion yen.
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more